A prospective multicenter study was performed to investigate the clinical and molecular results of intensified double induction therapy including high-dose cytarabine (ara-C) in combination with ATRA in newly diagnosed acute promyelocytic leukemia (APL), followed by consolidation and 3 years maintenance therapy. 
Introduction
The introduction of all-trans retinoic acid (ATRA) improved prognosis of acute promyelocytic leukemia (APL) when compared to standard chemotherapy with anthracyclines and cytarabine (ara-C).
1,2 By combining ATRA with chemotherapy, complete remission rates over 90% were achieved, and about 70% of patients with APL can probably be cured by first-line therapy. In spite of these encouraging results, further improvement of therapy is required, as about 30% of patients still die from their disease, mostly because they do not reach complete remission or due to relapse. bination with a potent chemotherapy. [1] [2] [3] [4] [5] [6] These observations suggest that the antileukemic efficacy of the chemotherapy is of critical importance for cure. The particularly high sensitivity of APL blasts against anthracyclines was demonstrated in early treatment studies. 9 Retrospective analyses showed that increasing doses of anthracyclines were associated with an improved overall and relapse-free survival. 10 Using a combination of anthracyclines and ATRA, a high rate of complete remission of 95% was induced with few side-effects. 11 However, the optimal conditions of APL treatment are unknown, such as the intensity and duration of chemotherapy, the optimal combination of chemotherapeutic drugs, and the modification of maintenance therapy. The future role of arsenic compounds in the treatment of APL also remains to be defined. 12 With regard to the combination of chemotherapy, the benefit of ara-C, in particular of high-dose ara-C, in APL treatment is under discussion. 10, 13, 14 The chemotherapy strategy of the AML Cooperative Group (AMLCG) for patients under the age of 60 years with newly diagnosed acute myeloid leukemia (AML) consisted of a double induction therapy with either standard-dose ara-C, daunorubicin, and 6-thioguanine in both cycles (TAD/TAD) or, randomly assigned, with high-dose ara-C and mitoxantrone in the second cycle (TAD/HAM). This was followed by TAD consolidation and 3 years monthly maintenance chemotherapy. 15 This strategy proved highly effective in the subgroup of patients with APL resulting in 3 and 10 year relapse-free survival rates of 59% and 47%, respectively, with a benefit of TAD/HAM. 16, 17 It was the concept of the present study for patients under the age of 60 years with newly diagnosed APL to combine the positive effects of the differentiating substance, ATRA, with a chemotherapy strategy of proven high curative potential. Induction therapy consisted of the simultaneous treatment with ATRA and intensified double induction chemotherapy (TAD/HAM), including high-dose ara-C and mitoxantrone. This was followed by TAD consolidation and maintenance chemotherapy, as previously reported. 15 Monitoring of minimal residual disease was performed using RT-PCR of PML/RAR␣ transcripts in order to assess quality and stability of remission on the molecular level. Here, we present the first clinical and molecular data of this study.
Patients and methods

Initial characteristics of the patient population
Eligibility criteria to be enrolled in the protocol included: newly diagnosed APL, age ranging from 16 to 60 years, cyto-genetic or molecular confirmation of the morphologic diagnosis APL by the presence of the specific translocation t (15;17) 18 or of the PML/RAR␣ hybrid gene by RT-PCR, 19, 20 no antecedent hematological or nonhematological malignancy, no cardiac contraindications against anthracyclines, and informed consent. At diagnosis, bone marrow slides were centrally reviewed. Morphological diagnosis of APL (AML M3 or M3 variant, M3v) was based on the FAB criteria. 21, 22 From 1 December 1994 to 8 June 1999, the date of evaluation, 62 adult patients under the age of 60 years with the morphological diagnosis APL were registered in 33 centers participating in the AML studies of the AMLCG. Eight patients were considered ineligible. In four of these eight patients, the diagnosis APL was not cytogenetically or molecularly confirmed. Three of the patients were excluded due to concomitant malignancy (cancers of lung, breast and testis), and one patient had a severe cardiac failure with contraindications against anthracyclines. Fifty-four cases were eligible. As this is an ongoing study, three of these patients are still undergoing therapy and have not yet completed the induction phase. Fifty-one cases were evaluable.
Protocol design Treatment plan:
Induction therapy consisted of TAD/HAM double induction chemotherapy and the simultaneous administration of 45 mg/m 2 ATRA daily until complete hematological remission (CR) or for a maximum of 90 days. The HAM course was given on day 21 after the start of TAD, independently of cytopenia. Two to 4 weeks after CR, one consolidation course of TAD was given, followed by a 3 years cyclic monthly maintenance chemotherapy. Molecular monitoring of PML/RAR␣ was scheduled after induction, after consolidation, and every 3 months during maintenance therapy. In case PCR positivity for PML/RAR␣ persisted after consolidation or reappeared during maintenance, patients underwent allogeneic bone marrow transplantation (BMT), if a related donor was available. Patients with PCR positivity not eligible for BMT received 45 mg/m 2 ATRA over 7 days in addition to the chemotherapy in each maintenance course.
Drug dosages and combinations of the chemotherapeutic regimens:
TAD: 6-Thioguanine (6-TG) 100 mg/m 2 every 12 h orally on days 3-9, ara-C 100 mg/m 2 by continuous intravenous infusion on days 1-2, and 100 mg/m 2 every 12 h by 30 min intravenous infusion on days 3-8, daunorubicin (DNR) 60 mg/m 2 by 30 min intravenous infusion on days 3-5. HAM: Ara-C 3 g/m 2 (in patients older than 60 years 1 g/m 2 ) every 12 h by 3 h intravenous infusion on days 1-3, mitoxantrone 10 mg/m 2 by 30 min intravenous infusion on days 3-5. Maintenance courses were given every 4 weeks: Ara-C 100 mg/m 2 every 12 h by subcutaneous injection on days 1-5, combined with a second drug being rotatingly either DNR 45 mg/m 2 by 30 min intravenous infusion on days 3 and 4 (course 1), or 6-TG 100 mg/m 2 every 12 h orally on days 1-5 (course 2), or cyclophosphamide 1 g/m 2 intravenous injection on day 3 (course 3), or again 6-TG (course 4), and restarting again with DNR (course 5). After a cumulative DNR dose of 540 mg/m 2 was reached, DNR was replaced by 6-TG in the respective courses. If the nadir of the absolute neutrophil counts was less than 500/mm 3 and/or of the platelet count less than 20 000/mm 3 after two consecutive maintenance courses, doses of all antileukemic drugs were reduced Leukemia by 50%. Further dose reductions were made accordingly. Maintenance treatment continued until the patient was in remission for 3 years.
Timing of the start of chemotherapy during induction:
In order to improve the coagulopathy before the start of chemotherapy or to prevent the induction of coagulopathy by chemotherapy, the first phase of induction therapy consisted of ATRA alone before adding TAD. In patients with significant coagulopathy at diagnosis, TAD was started after normalization of prothrombin time and of fibrinogen, or after 14 days at the latest. Patients without significant coagulopathy also received pretreatment with ATRA lasting for 1 week in order to prevent the induction of coagulopathy by chemotherapy. 23 The hemostatic disorder was classified significant if the fibrinogen level was less than 1.5 g/l or if the prothrombine time was prolonged (Ͼ1 s.d.). If only fibrinogen degradation products or D dimers were detectable, coagulopathy was considered not significant.
In order to prevent the ATRA syndrome, ATRA and TAD were started simultaneously in patients with initial white blood cell (WBC) counts over 5 × 10 9 /l or with M3v. In the case of rapidly rising WBC count, TAD was started according to the criteria established by the French protocols. 1, 6 Diagnosis of the ATRA syndrome was made clinically by the presence of otherwise unexplained fever, respiratory distress, weight gain, peripheral edema, pleural or pericardial effusions, unexplained hypotension, congestive heart failure, pulmonary edema, pulmonary infiltrates, acute renal failure, bone pain, and headache. 24, 25 The cases were identified by a detailed documentation of all signs of the ATRA syndrome in our case report forms. In each case with concurrent medical problems or in otherwise uncertain situations, the diagnosis of ATRA syndrome was discussed with the treating physician.
In the case of ATRA syndrome, ATRA was discontinued and dexamethasone started immediately at a dose of 10 mg twice daily by intravenous injection. Dexamethasone was continued until symptoms had disappeared, then ATRA was restarted. If the ATRA syndrome occurred before the beginning of chemotherapy, TAD was started immediately and dexamethasone was given simultaneously.
Supportive treatment during induction therapy:
Fresh frozen plasma was given if the fibrinogen level was less than 1.5 g/l or if the prothrombine time was prolonged (Ͼ1 s.d.). The goal of platelet transfusions was to maintain the platelet count above 50 × 10 9 /l until significant coagulopathy had resolved. The use of heparin or tranexamid acid was optional. During induction therapy and until the end of the hypoplastic period (defined until recovery of neutrophiles over 1 × 10 9 /l and platelets over 50 × 10 9 /l), oral antimicrobial prophylaxis consisted of amphothericin B, cotrimoxazol, and colistinsulfate. Febrile episodes were generally treated with empiric broad-spectrum antibiotics.
Molecular studies
For detection of PML/RAR␣ fusion transcripts, a nested RT-PCR was centrally performed in the III. Medizinische Klinik in Mannheim. Total RNA was extracted from bone marrow aspirates and reverse-transcribed as previously reported. 26, 27 To test for RNA and cDNA integrity, competitive RT-PCR of the abl gene was performed, as previously described. 28 PCR was set up as previously described 28 using forward primer TGTGC TGCAG CGCAT CCGCA CG and reverse primer GTGGT AGCCT GAGGA GTTGT CC (first step), and forward primer GCAGA GGATG AAGTG CTACG CC and reverse primer GGCAC TATCT CTTCA GAACT GC (second step). Amplification was performed in a DNA thermal cycler (BIOMETRA, Gö ttingen, Germany) using the hot start method and 16 cycles with the following cycle parameters: 94°C for 30 s, 60°C for 1 min, and 72°C for 1 min. After completion, a final extention step at 72°C for 10 min followed. Three microliters of first step amplification products were used in the second step amplification (36 cycles). Amplification products were analyzed on 1.5% TBE agarose gels after ethidium bromide staining.
For exclusion of false positive PCR results and for validation of results, the following controls were included in each experiment: As for two negative controls instead of patient's RNA (1) bidistilled water was used in cDNA synthesis and PCR amplification steps, and (2) cDNA derived from peripheral blood mononuclear cells (PBMNC) of a healthy individual. For two positive controls RT-PCR was carried out with (1) RNA derived from the PML/RAR␣ positive cell line NB4 (type L fusion transcript) and with (2) RNA derived from a previously diagnosed patient with type S fusion transcript. Identity of the amplified control DNA fragments was verified by DNA sequencing. 
Evaluation of response
A complete hematological remission (CR) was defined by reconstitution of a normal bone marrow cellularity with less than 5% blasts, by normalization of peripheral blood cell counts (neutrophils Ͼ1.5 × 10 9 /l, platelets Ͼ100 × 10 9 /l), and by disappearance of extramedullary leukemic manifestations. Molecular remission was defined as the disappearance of the specific PML/RAR␣ transcript amplification band (sensitivity 10 −4 ) identified at diagnosis by RT-PCR. After consolidation and during follow-up, PCR was determined to be positive if two consecutive PCRs performed at an interval of 4 weeks were positive. Conversion of PCR from positive to negative was also confirmed by a second follow-up PCR. In cases with uncertain results, further follow-up PCRs were performed.
Early death (ED) was defined as death during the induction phase before the patients recovered from chemotherapy-induced myelosuppression. Relapse was defined as persistent reinfiltration of the bone marrow by more than 5% leukemic blasts or a proven leukemic reinfiltration at any other site.
Overall survival (OS), event-free survival (EFS), and relapse-free survival (RFS) duration was calculated by the method of Kaplan and Meier. OS counted from the start of therapy until death, EFS from the start of therapy until nonachievement of remission or relapse of M3 leukemia or death. For RFS, relapse and death in remission were considered as events. Patients who underwent BMT were censored in the curves.
Results
Patient characteristics at diagnosis
The clinical and biological data of the 51 evaluable patients are shown in Table 1 . The median age was 43 years (range 16-60). Bleeding symptoms were present in 80% and significant coagulopathy in 72% of patients. The initial WBC counts were higher than 5 × 10 9 /l in 30% of the patients. M3v was diagnosed in 22% of cases. In 30% of patients with translocation t(15;17), additional karyotypic abnormalities were found. PML/RAR␣ transcripts were L type (bcr 1 and 2) in 58%, and S type (bcr 3) in 42% of the patients.
Results of induction therapy
Forty-seven of 51 patients (92%) achieved hematological CR. No patient was resistant against the therapy. Four patients (8%) died from early death (ED). The causes of death and the initial characteristics of these patients are shown in Table 2 . Three patients with M3v leukemia died during the first days of therapy due to bleeding complications (cerebral bleeding in two cases, pulmonary bleeding in one case). These patients had initial WBC counts of 54, 66 and 95 × 10 9 /l. One death The second induction cycle (HAM) was administered to all 48 patients who reached day 21 after the start of the first cycle (TAD), according to the protocol. The median time between the two induction cycles was 25 days (range 21-51), as the scheduled interval of 21 days was prolonged in some patients due to active infections or other side-effects of the therapy. Dose reduction of the induction chemotherapy was performed in none of the patients.
The median duration of ATRA treatment during induction was 48 days (range 14-75). In 33 patients (65%), the ATRA treatment was started before the chemotherapy by a median of seven days (1-12) . Thereby, the proportion of patients with significant coagulopathy was reduced from 70% at diagnosis to 49% at the start of TAD. The median time to hematological CR was 56 days (range 16-75). One patient died in CR on day 107 after the start of induction therapy from infection, before the consolidation course could be started.
Post-induction therapy and follow-up analysis
The TAD consolidation therapy was administered in 42 of the 46 patients that were alive at the time scheduled for consolidation therapy. All patients received the full chemotherapy dose. In four patients the consolidation was omitted due to severe infections (WHO grade у3) during induction. One patient died in CR from infection after consolidation. Of 45 patients that had reached the phase of maintenance, 13 (29%) patients did not receive maintenance therapy (including the four patients that had not received consolidation therapy) and in 11 (24%) cases, maintenance was terminated after 3-20 months. The reasons for the omission of maintenance therapy or premature termination were refusal by the patients in 31%, physicians' decision after previous severe infections in 26%, prolonged neutropenia between courses in 31%, chronic hepatitis in 6%, and vasculitis in 6% of the cases. In the 32 patients, who started maintenance therapy, the median duration of the therapy was 27 months (range 1 month to 3 years).
In June 1999, after a median observation time of 27 months (range 1 day to 4.4 years), the estimated actuarial 2 years OS and the 2 years EFS of the 51 evaluable patients were both 88% (79, 97) (Figure 1a and b) . The calculated 2 years RFS of the 47 patients that had entered remission was 96% (89.6, 100) (Figure 2 ). The median observation time for RFS was 25 months (range 47 days to 4.3 years). Three events were counted in calculating RFS. Two deaths occurred in CR, one after induction and one after consolidation therapy. One patient relapsed during follow-up, 3.8 years after he had entered first hematological CR. The initial WBC count of this patient was 12.3 × 10 9 /l. The relapse was cytogenetically and molecularly confirmed. Two cases underwent BMT.
There was no prognostic difference found for cases with cytogenetic abnormalities in addition to the translocation t(15;17) (OS: P = 0.57; EFS: P = 0.94; RFS: P = 0.34).
Molecular response
The results of the molecular analysis of the PML/RAR␣ transcript (sensitivity 10 −4 ) in correlation to treatment and to the
Figure 1
Overall survival and event-free survival was 88% (79, 97) after 2 years. Overall survival counted from the start of therapy until the date of the last observation or death. Tick marks indicate all patients alive (a). Event-free survival counted from the start of therapy to non-achievement of complete remission, relapse, death or to the last observation. Tick marks indicate patients without events (b). Two patients were censored at the time of bone marrow transplantation.
Figure 2
Relapse-free survival was 96% (90, 100) after 2 years. Relapse-free survival was counted from the date of complete remission until relapse or death. Tick marks indicate living patients in complete remission. One patient was censored at the time of bone marrow transplantation in first hematological remission due to a persistently positive PCR of PML/RAR␣. (10) 27 (90) a Represents the interval between diagnosis and the latest PCR during follow-up.
time after CR are shown in Table 3 . After induction therapy, the PCR was negative in 91% of patients and after consolidation in 92%. Follow-up analyses of PML/RAR␣ during maintenance were done in 30 of the 45 (67%) patients who had an initial identification of the fusion transcript. The median interval between follow-up PCRs during maintenance was 4 months (range 1-29). The median time from diagnosis to the latest PCR during follow-up was 18 months (range 4-45). One of the three patients who were PCR positive after induction became negative after consolidation and a second one during maintenance. The third patient remained persistently positive, and in two additional patients, PCR positivity reappeared resulting in three patients with a positive PCR during maintenance therapy. Two of these three patients underwent BMT, one case in first hematological CR. After BMT, the patient relapsed and died from APL. In the second patient a hematological relapse occurred before BMT. He was transplanted in second CR, and was in CR 7 months after BMT. The third patient was ineligible for BMT and received additional ATRA during maintenance chemotherapy. The PCR converted to negativity again, and has remained negative for the last 7 months with the patient still being in CR.
Side-effects of therapy
The ATRA syndrome occurred in eight of 51 (16%) patients between days 3 and 20 after the start of therapy. Each patient showed a combination of typical symptoms. In all patients the symptoms disappeared after treatment with dexamethasone. The median duration of dexamethasone therapy was 7 days (range 5-35). In none of the patients in whom ATRA was restarted after resolution of the symptoms was a recurrence of the ATRA syndrome observed. No patient died from the ATRA syndrome and all reached a continuous CR. Other most likely ATRA-related symptoms such as skin dryness, pseudotumor cerebri and hypercholesterolemia were observed only sporadically. Other adverse events during induction were mainly due to chemotherapy. Infections of WHO grades у3 were seen in 36% of patients. Other WHO grade у3 adverse events included hemorrhage in 16%, nausea and vomiting in 28%, diarrhea in 13%, and hepatotoxicity in 9% of patients. After consolidation, the rate of WHO grade у3 infections was 12%. Hepatotoxicity and nephrotoxicity WHO grade у3 were each seen in 2% of patients. Altogether, three patients died from infection, two patients after induction therapy, and one after consolidation therapy. No cardiac toxicity WHO grade у3 was observed. No serious events occurred during maintenance therapy.
Discussion
In comparison to other treatment strategies in newly diagnosed APL, the concept of the present study in patients aged under 60 years is characterized by a more intensive induction chemotherapy in combination with ATRA and by a prolonged myelosuppressive maintenance therapy. The concept of the chemotherapy is based on the strategies and results of the previous studies of the AMLCG which included all subtypes of AML. These treatment regimens also proved highly effective in patients with APL. 15, 17, 30 The induction therapy consisted of TAD/HAM double induction combined with ATRA. The intensification of induction chemotherapy was approached in two ways: (1) By the administration of a second chemotherapy cycle (HAM) at a median time of 25 days after the first cycle (TAD) independent from the response to the first cycle and from the degree of peripheral neutropenia. In other APL studies using simultaneous induction chemotherapy and ATRA, up to 60-90 days may have passed until a second chemotherapy cycle (consolidation therapy) was started. 1, 11, 14, 31, 32 (2) Furthermore, in our protocol, the second chemotherapy cycle was intensified incorporating high-dose ara-C and mitoxantrone. Both single agents and their combination (HAM) proved effective in the salvage therapy of refractory acute myeloid leukemia. [33] [34] [35] [36] [37] By their special timing of the drugs, the TAD and the HAM regimen also use a conditioning effect of ara-C on subsequently administered anthracyclines. 38 Postremission therapy consisted of one consolidation course with TAD and a monthly maintenance therapy over 3 years. As shown by the previous AML studies of the AMLCG, a 3 years myelosuppressive maintenance therapy prolonged the remission duration in patients with all AML subtypes significantly, as compared to consolidation alone. 30 Furthermore, beneficial effects of maintenance therapy on the duration of the CR in patients with APL have been shown by other studies before and after the availability of ATRA. 2, 31, 39 Despite a low relapse rate being achieved with the combination of ATRA and chemotherapy, 31 the optimal modification and duration of maintenance therapy, however, is still under discussion and should be addressed by randomized trials. The negativity of the PCR of PML/RAR␣ at the time of remission or during follow-up does not predict the cure reliably. 40 Therefore, it seems problematic to decide on maintenance therapy on the basis of the PCR results. More sensitive methods for the quantification of the minimal residual disease and the correlation of these results with the clinical data might be helpful in the future.
The cytogenetic or molecular proof of the translocation t(15;17) was a mandatory prerequisite for inclusion into this study, ensuring the homogeneity of the study population. Most patients with APL-like morphology without expression of the PML/RAR␣ fusion transcript fail to respond to ATRA. Such cases may carry the rare translocations t(11;17) or t(5;17), or represent a myeloid natural killer cell leukemia. [41] [42] [43] Furthermore, it may be difficult to distinguish some cases of APL from AML-M2 or AML-M4. As the majority of APL studies do not have such strict entry criteria, it can be assumed that some patients lacking PML/RAR␣ were also included in these trials, most likely with negative influence on the treatment results. Only in the recently reported studies, the Italian and the Spanish study, was a cytogenetical or molecular confirmation of the diagnosis mandatory for eligibility, as was the case in our study. In the APL-93 trial, the number of patients without cytogenetical or molecular proof of the diagnosis was small. Therefore, the results of these studies are the most appropriate ones for comparison with our data.
High WBC, M3v morphology, and older age are associated with a worse prognosis in APL. 1, 31, 32, 44 As shown by our data and also reported by others, M3v is associated with a significantly higher risk of early death.
1 M3v is commonly associated with high WBC counts, 22 which were reported to be a negative prognostic factor for relapse-free survival. 31, 32, 44 Regarding the initial characteristics of our patients, it should be emphasized that our study population includes 30% of patients with initial WBC counts over 5 × 10 9 /l. These high risk patients were not separately evaluated, as was the case in the APL-93 trial. 31 Furthermore, the rate of patients with the prognostically unfavorable subtype M3v (22%) was higher than in other studies. For comparison, the proportion of M3v was 12.6% in the Italian study, 12.8% in the APL-93 trial, and 19% in the Spanish study. 11, 14, 31 The higher rate of M3v in our study may be explained by the central review of initial bone marrow slides and by central karyotyping of all AML subtypes by our study group, leading to the detection of cases with M3v which are difficult to diagnose otherwise. Part of this difference could be explained by divergent interpretations of cases with M3v overlapping M3, as there is no standardized morphological classification of such overlapping cases. The median age of 43 years in our study was similar to the Italian, French and Spanish series. In contrast to our protocol, these studies included children and adults aged over 70 years. 11, 14, 31 Therefore, the comparability of the results is in some aspects limited.
The results of induction therapy show that all patients with translocation t(15;17) or PML/RAR␣ were responsive to ATRA and double induction. The rate of complete hematological CR was 92%. Similar CR rates were reached in other APL studies with ATRA and chemotherapy. 1, 3, 6, 11, 14, 31 The rate of molecular remission of PML/RAR␣ after induction therapy was 91%. The PCR negativity was reached within a median of 8 weeks. This indicates that the malignant clone or at least the number of leukemic cells that actively transcribe the fusion gene was reduced quickly and extensively by the induction therapy. In the Italian and the Spanish studies, less intensive induction chemotherapy was given, and PCR negativity of PML/RAR␣ was achieved more slowly (60.5% and 49%, respectively, after induction). Similar results, however, were seen after consolidation. PCR negativity was 98% in the Italian study and 93% in the Spanish study vs 92% in ours. 11, 14 It is presently unknown whether the speed with which PCR becomes negative is prognostic.
It was the concept of our study to treat all patients uniformly with simultaneous administration of ATRA and chemotherapy during induction. Only in patients without initial risk of the ATRA syndrome was a short pretreatment with ATRA alone Leukemia performed in order to reduce the risk of increased bleeding complications which might be caused by the combined effects of pre-existing coagulopathy and cell lysis after chemotherapy. 23 In this way, the rate of significant coagulopathy was reduced from 70% of patients at diagnosis to 49% at the start of chemotherapy. It is not possible to assess separately the contribution of this strategy to the treatment results. However, it should be kept in mind that no bleeding complications were observed in any patient who had normal fibrinogen and prothrombin time at the start of chemotherapy, whereas an exacerbation of coagulopathy and bleeding after the start of chemotherapy could sometimes be observed before the availability of ATRA. 9, 45 From the start of therapy until the recovery of blood counts, severe (WHO grade у3) bleeding and infection were the most frequent adverse events seen in 16% and 36% of patients, respectively. Aside from the higher rate of bleeding complications in APL, the rate of infections and other events was comparable to the results recently reported in 725 patients of the AML 86 trial of the AMLCG. 15 In the present trial, the early death rate is 8%, and the rate of death in CR is 4%, which is similar to other APL studies. 1, 3, 5, 6, 11, 31 The rate of ATRA syndrome of 16% in our patients is similar to the rate of 15% in the APL-93 trial. 31, 46 The PCR results during follow-up in our series correlated well with the clinical course of the patients, indicating stability of remissions also on the molecular level. As reported previously, a negativity of the PCR seems to be an uncertain parameter to assess the probability of cure in the individual case, as relapses also occurred in such cases. 40 Positivity of PML/RAR␣, however, is generally considered to predict a subsequent relapse, as also shown in our patients. 40, [47] [48] [49] [50] [51] In our study, the median interval between follow-up PCRs was 4 months. A regular PCR monitoring in intervals of at least 3 months, however, is recommended to recognize patients with an imminent relapse more certainly, since the median time from reappearance of PCR positivity to hematological relapse was 3 months in a large series of patients. 40 The estimated 1 and 2 years rate of OS and of EFS was 88%, and of RFS 96%, respectively. As compared to the other studies with a similar median observation time, 11, 31, 40 a particularly low relapse rate was observed in our patients. However, a longer follow-up is essential to assess the cure rate that can be achieved.
In conclusion, the clinical and molecular data of our study indicate a high antileukemic efficacy of this treatment strategy in patients with newly diagnosed APL. By TAD/HAM double induction therapy in combination with ATRA, followed by TAD consolidation and monthly maintenance chemotherapy, a rapid and extensive reduction of the malignant clone, and a high rate of stable remission can be achieved. A favorable treatment result was also observed in patients with a high initial WBC count associated with a higher risk of relapse in other studies.
Our results suggest that the intensity of the chemotherapy combined with ATRA is one of the factors which has a critical influence on the outcome in patients with newly diagnosed APL. A randomized trial would provide the possibility of assessing the value of an induction therapy including ATRA and high-dose ara-C in comparison to standard-dose ara-C. Such a trial could be of particular importance in patients with poor prognostic factors.
